Global Recombinant Insulin Analogue Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Publication ID:

GIR042512945

Publication Date:

April 24, 2025

Pages:

Publisher:

GIR

Countries:

Global [1]

USD 3,480.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Recombinant Insulin Analogue market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
Recombinant insulin analogues are not easy to cause heterogenous allergic reaction in patients, with small side effects; It can simulate the physiological insulin secretion curve of human body, accurately adjust the blood glucose concentration of human body, reduce the risk of hypoglycemia, and further improve the safety and effectiveness.
This report is a detailed and comprehensive analysis for global Recombinant Insulin Analogue market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Recombinant Insulin Analogue market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Recombinant Insulin Analogue market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Recombinant Insulin Analogue market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Recombinant Insulin Analogue market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Recombinant Insulin Analogue
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Recombinant Insulin Analogue market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Gan & Lee Pharmaceuticals Co., Ltd, The United Laboratories International Holdings Limited, Tonghua Dongbao Pharmaceutical Co., Ltd, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Recombinant Insulin Analogue market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Quick-Acting
Medium Effect
Long-Lasting
Super Long-Acting
Market segment by Application
Type 1 Diabetes
Type 2 Diabetes
Major players covered
Novo Nordisk A/S
Eli Lilly and Company
Sanofi
Gan & Lee Pharmaceuticals Co., Ltd
The United Laboratories International Holdings Limited
Tonghua Dongbao Pharmaceutical Co., Ltd
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Recombinant Insulin Analogue product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Recombinant Insulin Analogue, with price, sales quantity, revenue, and global market share of Recombinant Insulin Analogue from 2020 to 2025.
Chapter 3, the Recombinant Insulin Analogue competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Recombinant Insulin Analogue breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Recombinant Insulin Analogue market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Recombinant Insulin Analogue.
Chapter 14 and 15, to describe Recombinant Insulin Analogue sales channel, distributors, customers, research findings and conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Recombinant Insulin Analogue Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Quick-Acting
1.3.3 Medium Effect
1.3.4 Long-Lasting
1.3.5 Super Long-Acting
1.4 Market Analysis by Application
1.4.1 Overview: Global Recombinant Insulin Analogue Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Type 1 Diabetes
1.4.3 Type 2 Diabetes
1.5 Global Recombinant Insulin Analogue Market Size & Forecast
1.5.1 Global Recombinant Insulin Analogue Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Recombinant Insulin Analogue Sales Quantity (2020-2031)
1.5.3 Global Recombinant Insulin Analogue Average Price (2020-2031)
2 Manufacturers Profiles
2.1 Novo Nordisk A/S
2.1.1 Novo Nordisk A/S Details
2.1.2 Novo Nordisk A/S Major Business
2.1.3 Novo Nordisk A/S Recombinant Insulin Analogue Product and Services
2.1.4 Novo Nordisk A/S Recombinant Insulin Analogue Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Novo Nordisk A/S Recent Developments/Updates
2.2 Eli Lilly and Company
2.2.1 Eli Lilly and Company Details
2.2.2 Eli Lilly and Company Major Business
2.2.3 Eli Lilly and Company Recombinant Insulin Analogue Product and Services
2.2.4 Eli Lilly and Company Recombinant Insulin Analogue Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Eli Lilly and Company Recent Developments/Updates
2.3 Sanofi
2.3.1 Sanofi Details
2.3.2 Sanofi Major Business
2.3.3 Sanofi Recombinant Insulin Analogue Product and Services
2.3.4 Sanofi Recombinant Insulin Analogue Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Sanofi Recent Developments/Updates
2.4 Gan & Lee Pharmaceuticals Co., Ltd
2.4.1 Gan & Lee Pharmaceuticals Co., Ltd Details
2.4.2 Gan & Lee Pharmaceuticals Co., Ltd Major Business
2.4.3 Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Product and Services
2.4.4 Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 Gan & Lee Pharmaceuticals Co., Ltd Recent Developments/Updates
2.5 The United Laboratories International Holdings Limited
2.5.1 The United Laboratories International Holdings Limited Details
2.5.2 The United Laboratories International Holdings Limited Major Business
2.5.3 The United Laboratories International Holdings Limited Recombinant Insulin Analogue Product and Services
2.5.4 The United Laboratories International Holdings Limited Recombinant Insulin Analogue Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 The United Laboratories International Holdings Limited Recent Developments/Updates
2.6 Tonghua Dongbao Pharmaceutical Co., Ltd
2.6.1 Tonghua Dongbao Pharmaceutical Co., Ltd Details
2.6.2 Tonghua Dongbao Pharmaceutical Co., Ltd Major Business
2.6.3 Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Product and Services
2.6.4 Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Tonghua Dongbao Pharmaceutical Co., Ltd Recent Developments/Updates
3 Competitive Environment: Recombinant Insulin Analogue by Manufacturer
3.1 Global Recombinant Insulin Analogue Sales Quantity by Manufacturer (2020-2025)
3.2 Global Recombinant Insulin Analogue Revenue by Manufacturer (2020-2025)
3.3 Global Recombinant Insulin Analogue Average Price by Manufacturer (2020-2025)
3.4 Market Share Analysis (2024)
3.4.1 Producer Shipments of Recombinant Insulin Analogue by Manufacturer Revenue ($MM) and Market Share (%): 2024
3.4.2 Top 3 Recombinant Insulin Analogue Manufacturer Market Share in 2024
3.4.3 Top 6 Recombinant Insulin Analogue Manufacturer Market Share in 2024
3.5 Recombinant Insulin Analogue Market: Overall Company Footprint Analysis
3.5.1 Recombinant Insulin Analogue Market: Region Footprint
3.5.2 Recombinant Insulin Analogue Market: Company Product Type Footprint
3.5.3 Recombinant Insulin Analogue Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Recombinant Insulin Analogue Market Size by Region
4.1.1 Global Recombinant Insulin Analogue Sales Quantity by Region (2020-2031)
4.1.2 Global Recombinant Insulin Analogue Consumption Value by Region (2020-2031)
4.1.3 Global Recombinant Insulin Analogue Average Price by Region (2020-2031)
4.2 North America Recombinant Insulin Analogue Consumption Value (2020-2031)
4.3 Europe Recombinant Insulin Analogue Consumption Value (2020-2031)
4.4 Asia-Pacific Recombinant Insulin Analogue Consumption Value (2020-2031)
4.5 South America Recombinant Insulin Analogue Consumption Value (2020-2031)
4.6 Middle East & Africa Recombinant Insulin Analogue Consumption Value (2020-2031)
5 Market Segment by Type
5.1 Global Recombinant Insulin Analogue Sales Quantity by Type (2020-2031)
5.2 Global Recombinant Insulin Analogue Consumption Value by Type (2020-2031)
5.3 Global Recombinant Insulin Analogue Average Price by Type (2020-2031)
6 Market Segment by Application
6.1 Global Recombinant Insulin Analogue Sales Quantity by Application (2020-2031)
6.2 Global Recombinant Insulin Analogue Consumption Value by Application (2020-2031)
6.3 Global Recombinant Insulin Analogue Average Price by Application (2020-2031)
7 North America
7.1 North America Recombinant Insulin Analogue Sales Quantity by Type (2020-2031)
7.2 North America Recombinant Insulin Analogue Sales Quantity by Application (2020-2031)
7.3 North America Recombinant Insulin Analogue Market Size by Country
7.3.1 North America Recombinant Insulin Analogue Sales Quantity by Country (2020-2031)
7.3.2 North America Recombinant Insulin Analogue Consumption Value by Country (2020-2031)
7.3.3 United States Market Size and Forecast (2020-2031)
7.3.4 Canada Market Size and Forecast (2020-2031)
7.3.5 Mexico Market Size and Forecast (2020-2031)
8 Europe
8.1 Europe Recombinant Insulin Analogue Sales Quantity by Type (2020-2031)
8.2 Europe Recombinant Insulin Analogue Sales Quantity by Application (2020-2031)
8.3 Europe Recombinant Insulin Analogue Market Size by Country
8.3.1 Europe Recombinant Insulin Analogue Sales Quantity by Country (2020-2031)
8.3.2 Europe Recombinant Insulin Analogue Consumption Value by Country (2020-2031)
8.3.3 Germany Market Size and Forecast (2020-2031)
8.3.4 France Market Size and Forecast (2020-2031)
8.3.5 United Kingdom Market Size and Forecast (2020-2031)
8.3.6 Russia Market Size and Forecast (2020-2031)
8.3.7 Italy Market Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Recombinant Insulin Analogue Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Recombinant Insulin Analogue Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Recombinant Insulin Analogue Market Size by Region
9.3.1 Asia-Pacific Recombinant Insulin Analogue Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Recombinant Insulin Analogue Consumption Value by Region (2020-2031)
9.3.3 China Market Size and Forecast (2020-2031)
9.3.4 Japan Market Size and Forecast (2020-2031)
9.3.5 South Korea Market Size and Forecast (2020-2031)
9.3.6 India Market Size and Forecast (2020-2031)
9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
9.3.8 Australia Market Size and Forecast (2020-2031)
10 South America
10.1 South America Recombinant Insulin Analogue Sales Quantity by Type (2020-2031)
10.2 South America Recombinant Insulin Analogue Sales Quantity by Application (2020-2031)
10.3 South America Recombinant Insulin Analogue Market Size by Country
10.3.1 South America Recombinant Insulin Analogue Sales Quantity by Country (2020-2031)
10.3.2 South America Recombinant Insulin Analogue Consumption Value by Country (2020-2031)
10.3.3 Brazil Market Size and Forecast (2020-2031)
10.3.4 Argentina Market Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Recombinant Insulin Analogue Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Recombinant Insulin Analogue Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Recombinant Insulin Analogue Market Size by Country
11.3.1 Middle East & Africa Recombinant Insulin Analogue Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Recombinant Insulin Analogue Consumption Value by Country (2020-2031)
11.3.3 Turkey Market Size and Forecast (2020-2031)
11.3.4 Egypt Market Size and Forecast (2020-2031)
11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
11.3.6 South Africa Market Size and Forecast (2020-2031)
12 Market Dynamics
12.1 Recombinant Insulin Analogue Market Drivers
12.2 Recombinant Insulin Analogue Market Restraints
12.3 Recombinant Insulin Analogue Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Recombinant Insulin Analogue and Key Manufacturers
13.2 Manufacturing Costs Percentage of Recombinant Insulin Analogue
13.3 Recombinant Insulin Analogue Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Recombinant Insulin Analogue Typical Distributors
14.3 Recombinant Insulin Analogue Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

Companies Mentioned:

Novo Nordisk A/S
Eli Lilly and Company
Sanofi
Gan & Lee Pharmaceuticals Co., Ltd
The United Laboratories International Holdings Limited
Tonghua Dongbao Pharmaceutical Co., Ltd

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂